The scientific rationale behind the approach rests on a rethinking of where the most informative biomarkers in the body actually reside. Current clinical liquid biopsy approaches, in which fragments of tumor-derived DNA or other molecular signals are hunted in a patient’s bloodstream, have transformed oncology in recent years, but they face a persistent limitation: sensitivity. Tumor DNA shed into the blood can be heavily diluted across the roughly five liters of the circulating vascular compartment, and for many cancers, particularly at early stages or in regions of low tumor burden, the signal can fall below the detection threshold of even the most advanced sequencing and assay platforms. Blood, in other words, is a convenient but sometimes whisper-quiet medium for detecting the molecular echoes of a small metastatic deposit.

The research team argues that a far richer source of information lies in a compartment that liquid biopsy has largely ignored: the lymphatic system. Their reasoning draws on the Revised Starling Principle, the modern formulation of the physiological rules governing fluid exchange between blood vessels, tissues and the lymphatic circulation. Under this principle, lymphatic vessels, rather than venules and veins, absorb the majority of interstitial fluid in most tissues. That fluid, along with the proteins, cells and cell-free nucleic acids it carries, is funneled through lymphatic channels into regional lymph nodes, which act as biological filters and immunological processing stations. In practical terms, this means that molecules shed by tumor cells in a tissue are concentrated along a drainage route that terminates in a small, anatomically identifiable structure, the sentinel or regional lymph node, rather than dispersed throughout the entire bloodstream.

This anatomy makes lymphatic-derived biomarkers an attractive target for assessing metastatic risk. Lymph nodes are, after all, the first and most common destination for the spread of many solid tumors, including head and neck cancers, breast cancers and melanomas. A molecular readout obtained directly from a lymph node could, in principle, reveal the presence and character of metastatic cells far earlier and with far greater sensitivity than a blood test, because the analyte is collected at the point of concentration rather than after dilution. The catch has always been access. Lymph nodes are small, embedded in fatty and vascular tissue, and traditionally require surgical excision, or at minimum a core needle biopsy, to obtain material for analysis. Surgical sampling carries costs in operating time, anesthesia, scarring and, in the case of sentinel node procedures, the risk of lymphedema and other complications. The field has lacked a genuinely minimally invasive technique for reaching into a lymph node and retrieving molecular material without removing it.

His@PDA@Needle was designed to close that gap. The platform is built on a modified acupuncture needle, an instrument chosen for its extraordinary fineness, which allows it to be introduced into lymph node tissue with minimal disruption to surrounding structures. The modifications, indicated by the device’s name, involve surface functionalization of the needle with a histidine-based layer and polydopamine chemistry, an approach that equips the fine needle to capture and carry back DNA biomarkers from the lymph node microenvironment. Polydopamine coatings are widely used in biomedical engineering because they adhere robustly to diverse surfaces and can be further functionalized with ligands that bind specific molecular targets. By combining these materials on an acupuncture needle substrate, the team created a sampling device fine enough for minimally invasive insertion yet chemically tuned to harvest nucleic acid material suitable for downstream molecular profiling.

The performance of the platform was evaluated in two complementary settings. First, the researchers tested it in mouse footpad xenograft models, a well-established experimental system in which tumor cells are implanted in the footpad of a mouse and drain naturally to the popliteal lymph node, allowing lymphatic metastasis to be studied in a controlled setting. This model allowed the team to assess whether the modified needle could retrieve tumor-derived DNA from lymphatic tissue in a living organism. Second, and critically, the platform was applied to lymph node samples derived from patients with head and neck cancer, providing an initial window into how the technique might perform on human clinical material. The combination of an animal model and human tissue samples gave the study both a controlled proof of principle and a preliminary translational signal.

The most striking practical claim of the study concerns invasiveness. Compared with conventional lymph node biopsy, in which a node is surgically removed, the DNA sampling approach enabled by the modified needle is significantly less invasive. A fine needle insertion, closer in character to the fine-needle aspirations already familiar in oncology clinics than to an operating room procedure, could in principle be performed with far less tissue disruption, lower procedural burden and reduced risk of complications. For patients, that difference matters: less pain, faster recovery and a lower barrier to repeated sampling. For researchers and clinicians, it opens the possibility of serial molecular monitoring, sampling the same nodal basin at multiple time points during treatment to track how a tumor’s molecular profile evolves under therapy, something that is rarely feasible with excisional biopsy.

The authors are careful, and appropriately so, about the intended scope of the technology. His@PDA@Needle is presented as a molecular profiling tool designed to complement existing histopathological evaluations, not as a standalone instrument for direct clinical diagnosis. Histopathology, the microscopic examination of stained tissue sections by a pathologist, remains the gold standard for diagnosing lymph node metastasis, and it provides information, such as tissue architecture, cell morphology and the spatial relationships of tumor cells to lymphoid structures, that no molecular assay currently replicates. What a minimally invasive molecular sampling tool adds is a different layer of information: the genetic and epigenetic signatures of the material present in the node, which can reveal mutations, tumor lineage and other molecular features that inform prognosis and treatment selection. The two approaches are positioned as partners, with the needle offering a low-burden route to molecular data and pathology offering the definitive structural assessment.

The broader significance of the work lies in the paradigm it proposes. If lymphatic-derived biomarkers can be shown, in larger and more definitive studies, to outperform blood-based markers for detecting nodal metastasis, the entire architecture of liquid biopsy could shift. Instead of asking a blood draw to detect a signal that has been diluted across the whole circulation, clinicians could sample the lymphatic compartment directly, where tumor-derived molecules concentrate on their way through the nodes. The Revised Starling Principle provides the physiological foundation for this idea, and the modified acupuncture needle provides the first practical instrument for acting on it. The study was published under DOI 10.1002/imm3.70052, and the authors have disclosed that Dongdong Liu holds a patent related to the research, under application number 202510337544.5, with no other competing interests declared.

Much work remains before a modified acupuncture needle becomes a fixture in the cancer clinic. The validation reported to date is preliminary, and the technique will need to demonstrate its sensitivity, specificity and safety across larger patient cohorts, multiple cancer types and diverse clinical settings before it can influence diagnostic pathways. Questions about sampling adequacy, standardization of the coating chemistry, the molecular assays best paired with the harvested DNA, and the procedural training required will all need answers. But the conceptual advance is clear and consequential: the lymphatic system, long treated as a structural highway for cancer spread and a surgical target for staging, is now being reframed as a rich, accessible reservoir of molecular information. A needle fine enough to have served healers for millennia, re-engineered with modern materials chemistry, may be the instrument that finally opens that reservoir to molecular medicine.

Subject of Research: Minimally invasive lymph node sampling for cancer biomarker analysis using a surface-modified acupuncture needle

Article Title: New modified acupuncture needle enables minimally invasive lymph node sampling for molecular profiling

Article References: New modified acupuncture needle enables minimally invasive lymph node sampling for molecular profiling. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: acupuncture needle, lymph node, liquid biopsy, molecular profiling, lymphatic system, Revised Starling Principle, DNA biomarkers, head and neck cancer, metastasis, minimally invasive, polydopamine coating, iMetaMed

The core problem the model addresses is that vaccination is not simply a matter of injecting antigen and waiting for T cells to attack. Immune activation depends on a delicate choreography: antigen must meet immature antigen-presenting cells in peripheral tissue, and those activated cells must then travel through lymphatic vessels to lymph nodes, where they encounter naive T cells ready to be converted into tumor-killing effectors. Each step in this relay is shaped by anatomy. Blood flow rates, lymphatic drainage patterns, vessel permeability, and the specific lymph nodes draining a given tissue all influence whether the immune system mounts a vigorous response or a feeble one. Tumors complicate matters further by releasing suppressive factors such as TGF-beta, IL-10, VEGF, and lactic acid, which circulate systemically and can dampen immune priming in lymph nodes far from the tumor itself.

Existing computational models have captured fragments of this system, but the new framework is notable for its scope. It divides the body into interconnected compartments representing the heart, brain, lungs, liver, spleen, gastrointestinal tract, kidneys, breast tissue, skeletal muscle, bone, and a skin network split into six regions, each with its own draining lymph nodes. Arterial, venous, and lymphatic circulations link these compartments, and a modified version of Starling’s law governs fluid exchange between vessels and tissue. Crucially, each organ is paired with upstream and downstream lymph nodes arranged in series, each equipped with its own blood supply through high endothelial venules and its own afferent and efferent lymphatic pathways. This architecture allows the model to track where in the body T cell activation can actually occur, rather than assuming a single generic lymph node handles all priming.

At the cellular level, the model follows tumor cells, naive T cells born in the thymus, immature and activated antigen-presenting cells generated mainly in the bone marrow and skin, and effector T cells that proliferate in response to IL-2 and migrate into tumors. At the molecular level, it simulates antigen, inflammatory cytokines, IL-2, VEGF, and a lumped tumor-derived suppressive factor. Because quantitative data on individual suppressive pathways remain scarce, the researchers modeled tumor-induced immunosuppression as a single aggregate factor, an acknowledged simplification that keeps the system tractable while capturing its dominant effect. Naive T cells can only be activated in lymph nodes and the spleen, never in ordinary tissue, which makes the location and suppression state of those lymphoid organs decisive.

To quantify where activation is possible, the team introduced a concept called activation potential, essentially the probability that a given lymph node or the spleen can support T cell priming at a given moment. This probability decays exponentially as suppressive factor concentration rises. Simulations of a patient with a breast tumor vaccinated in the left arm revealed that suppressive factor accumulates fastest in the lymph nodes closest to the tumor’s drainage pathway, silencing them early. When suppressive factor production was raised by 40 percent, the window for effective vaccination in tumor-draining upstream lymph nodes shrank from roughly five days to just two or three. The model also showed that because all blood passes through the lungs, upstream lymph nodes draining the lungs are suppressed faster than their downstream counterparts, a subtle anatomical effect that simpler models would entirely miss.

The researchers then evaluated vaccination across every major organ and skin region, scoring outcomes with three metrics: activation site occupancy, which measures local activation in each lymphoid tissue; overall immune hotness, reflecting the total systemic expansion of effector T cells; and tumor immune hotness, the fraction of those cells that actually reach the tumor. The results were striking. For patients whose tumors produced high levels of suppressive factor, the farther the vaccination site sat from the tumor, the stronger the immune response, and injecting vaccine directly into the tumor performed poorly because tumor-draining lymph nodes were already saturated with suppressive signals. Conversely, patients with high tumor antigen production were far less sensitive to vaccination site, because tumor-released antigen was already activating lymph nodes throughout the body, making the vaccine a helpful supplement rather than the primary trigger.

Timing and route mattered as well. Intradermal and intramuscular vaccination produced similar systemic responses regardless of which skin region was used, suggesting both are viable delivery routes. In patients with high suppressive factor, early vaccination at day 7 favored internal sites in a specific order, with the gastrointestinal tract, spleen, bone, brain, and lungs outperforming the tumor, kidneys, and liver. Vaccination in the liver and kidneys proved ineffective across the board, because antigen injected there was rapidly cleared through vascular and lymphatic transport before antigen-presenting cells could take it up. For low-suppression patients with abundant antigen, the lungs yielded the strongest response. Notably, the model suggested that dual-site vaccination, combining an intratumoral dose with a distant one, could help patients whose tumors secrete high levels of suppressive factors.

Because running thousands of mechanistic simulations is computationally expensive, the team trained a random forest machine learning algorithm on the model’s outputs. The surrogate reproduced the mechanistic predictions with a correlation of 0.99, enabling rapid exploration of virtual patient populations and feature importance analysis. That analysis ranked tumor antigen level as the strongest predictor of tumor immune hotness, followed by suppressive factor level, vaccination timing, and vaccination site. When the researchers simulated vaccination on eight different days across five delivery routes for patients with unknown antigen and suppressive factor profiles, the estimated overall efficacy was highest for lung vaccination at 23.75 percent, followed by spleen at 23 percent, gastrointestinal and superficial routes near 21.5 to 21.75 percent, and intratumoral delivery last at 16 percent.

The model was calibrated and evaluated against experimental and clinical datasets covering antigen-dependent T cell activation, suppression by tumor-derived factors, and therapeutic vaccination responses, and the authors report good agreement with observations. They emphasize that the framework is a first step toward true digital twins of the immune system, which would require patient-specific parameterization from clinical and omics data, calibration against longitudinal measurements, and prospective validation. Still, the central message is already clear: identical vaccination protocols may produce substantially different immune responses across patients, and the optimal route and schedule depend on measurable features of each person’s tumor, particularly how much antigen and suppressive factor it releases. If validated prospectively, this kind of whole-body simulation could one day let oncologists test a vaccine virtually, choosing the site and timing most likely to turn a cold tumor hot before treatment ever begins.

Subject of Research: A physiologically-based pharmacokinetic/pharmacodynamic model for optimizing cancer vaccination strategies

Article Title: Optimizing Cancer Vaccinations Using a Physiologically‐Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model

Article References: R. Nikmaneshi, M., P. Padera, T., & L. Munn, L. (2026). Optimizing Cancer Vaccinations Using a Physiologically‐Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model. Advanced Science, Article e78044. https://doi.org/10.1002/advs.78044

Image Credits: AI Generated

DOI: 10.1002/advs.78044

Keywords: cancer vaccines, PBPK/PD modeling, immunotherapy, lymphatic system, T cell activation, tumor microenvironment, suppressive factors, personalized medicine, machine learning, systems immunology, lymph nodes, digital twin

The scale of the problem the review addresses is hard to overstate. Obesity has become a global public health crisis, and according to the World Obesity Federation’s 2025 atlas its continued rise poses significant risks for cardiovascular disease, type 2 diabetes and several cancers, while reducing life expectancy. Traditional explanations have centered on energy balance, adipose tissue expansion and chronic low-grade inflammation. What has been missing, the authors contend, is a systematic account of how the lymphatic vasculature participates in this pathology. Their review, published on 25 September 2026, sets out to map the mechanisms of interaction between lymphatic dysfunction and obesity, and to ask which direction the causality runs, a question that remains only partially answered.

Understanding the argument requires appreciating how unusual lymphatic vessels are at the structural level. Unlike blood vessels, collecting lymphatics are lined by endothelial cells joined by specialized button-like junctions that act as flaps, allowing fluid, proteins and immune cells to enter freely while preventing backflow. In the intestine, these vessels form lacteals, blind-ended capillaries in each villus that absorb dietary fat packaged into chylomicrons. The junctions between lacteal endothelial cells are remarkably plastic: work cited in the review showed that zippering these junctions shut in mice protects against diet-induced obesity by limiting fat uptake, while fibroblast subsets in the villi regulate lacteal integrity through YAP/TAZ-driven production of vascular endothelial growth factor C, or VEGF-C. In other words, the architecture of the lymphatic drainage system directly tunes how many calories the gut absorbs.

The molecular machinery governing lymphatic identity and function is equally central to the story. The transcription factor Prox1 induces the lymphatic endothelial phenotype, working with COUP-TFII to specify cell fate, while the VEGF-C/VEGFR-3 signaling axis drives lymphangiogenesis, the growth of new lymphatic vessels. VEGFR-3 signaling is required for button junction formation, and ligand-induced heterodimerization with VEGFR-2 shapes phosphorylation patterns in lymphatic endothelial cells. Other players refine the network further: semaphorin 3A, neuropilin-1 and plexin-A1 are needed for lymphatic valve formation, FOXC2 and fluid shear stress stabilize vessels after birth, and eNOS controls valve specification through beta-catenin signaling. When any of these pathways falter, the consequences ripple outward, because lymphatics do far more than drain fluid. They mediate macrophage reverse cholesterol transport, remove cholesterol from peripheral tissues via SR-BI-mediated HDL transport, and serve as gatekeepers that shape immune tolerance through molecules such as PD-L1.

Against this backdrop, the evidence that obesity damages lymphatics is strikingly consistent. Mouse studies have shown that obesity impairs lymphatic fluid transport and dendritic cell migration to lymph nodes, and that chronic high-fat feeding degrades collecting vessel function even before gross metabolic disease appears. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration, and ApoE-deficient animals show multiple facets of lymphatic failure, including valve dysfunction on western diets. In obese animals, mesenteric lymph nodes display increased fibrosis and altered immune cellularity, and obesity-associated lymph leakage impairs the trafficking of lipids, lipophilic drugs and antigens from the intestine. Mechanistically, inflammatory cytokines appear to be key culprits: tumor necrosis factor alpha inhibits lymphatic pumping through the NF-kappaB and inducible nitric oxide synthase pathway, and inflammatory mediators disrupt endothelial barrier function. Obesity, in this framing, is an environment in which lymphatic vessels progressively choke.

Crucially, the review emphasizes that the damage is not merely collateral. Lymphatic insufficiency feeds back into metabolic disease. Mesenteric lymphatic dysfunction has been shown to promote insulin resistance, positioning the lymphatic system as a potential treatment target rather than a passive victim. Deletion of the fatty acid transporter CD36 specifically in lymphatic endothelial cells associates with visceral obesity and insulin resistance, while RAMP1 signaling deletion enhances diet-induced obesity and fat absorption through intestinal lacteals. In Prox1-haploinsufficient mice, which have inherently compromised lymphatics, restoring lymphatic function rescued the obese phenotype, one of the most direct demonstrations that lymphatic failure can cause obesity rather than simply accompany it. Lymphatic vessel insufficiency in hypercholesterolemic mice also alters lipoprotein levels and promotes atherosclerosis, extending the loop to cardiovascular disease.

The immune dimension adds another layer of complexity. Adipose tissue in obesity accumulates macrophages, and a paracrine loop between adipocytes and macrophages, driven by free fatty acids and tumor necrosis factor alpha, aggravates inflammation. Adipokines modulate this crosstalk: leptin, elevated in obesity, compromises lymphatic endothelial cell homeostasis by impairing tube formation and proliferation, and leptin-VEGF crosstalk has been implicated in excess body mass and related disorders. Adiponectin, by contrast, protects the system, modulating lymphatic vessel formation and reducing lymphedema. T lymphocytes negatively regulate lymph node lymphatic vessel formation, Th2 cytokines inhibit lymphangiogenesis, and transforming growth factor beta 1 blockade accelerates lymphatic regeneration during wound repair. Specialized pro-resolving mediators such as lipoxins interact with the lymphatic system to resolve inflammation, suggesting that the vessels are active participants in the inflammatory arc of obesity, from ignition to resolution.

What makes the review timely is its treatment implications. The authors highlight that obesity-induced lymphatic dysfunction is reversible with weight loss, and that exercise training improves obesity-related lymphatic dysfunction in animal models. A lymphoscintigraphic study found that lower extremity lymphatic function can be predicted by body mass index, linking clinical imaging to the mechanistic work. Inhibition of inflammation and inducible nitric oxide synthase improves lymphatic function in obesity, and a case report described semaglutide treatment in a patient with extreme obesity and massive lymphedema, hinting that the new generation of metabolic drugs may act partly through lymphatic pathways. Manual lymphatic drainage has been shown to alter adipokine and cytokine concentrations and markers of insulin resistance in patients with abnormal body mass index, while electroacupuncture combined with intradermal needling has been reported to influence serum markers of intestinal lymphatic function in simple obesity. Even GLP-2 has been shown to stimulate lacteal contractility and enhance chylomicron transport when the enteric nervous system is intact.

The therapeutic frontier the review sketches is correspondingly broad. Pharmacological modulation of the VEGF-C/VEGFR-3 axis could either promote lymphatic growth where vessels have failed or, in the intestinal context, be tuned to limit fat absorption, since blockade of VEGF-C and VEGF-D has been shown to modulate adipose tissue inflammation and improve metabolic parameters under high-fat diet conditions. Apelin, which inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity, represents another candidate pathway, as do receptors such as GPR182, recently identified as a lipoprotein receptor for dietary fat absorption, and the ERAD machinery protein AIDA, which selectively downregulates fat synthesis enzymes to retard intestinal fat uptake and prevent obesity. Targeting lymphatic muscle cells, valve function and junctional zippering each offer distinct intervention points, though the authors are careful to note that the directionality of causality between lymphatic dysfunction and obesity is not yet fully resolved, and that much of the evidence remains preclinical.

The broader significance of the work lies in reframing. If the lymphatic system sits at the junction of fat absorption, cholesterol trafficking, immune signaling and inflammation resolution, then it is not a peripheral curiosity in metabolic disease but a potential control node. The review, funded by the National Natural Science Foundation of China, systematically assembles the case that protecting or restoring lymphatic function could complement diet, exercise and incretin-based therapies, and that lymphatic biomarkers might one day identify patients at risk of obesity-driven metabolic complications before they manifest. It also raises an urgent clinical question: with obesity-linked lymphedema rising alongside waistlines worldwide, understanding the bidirectional crosstalk between fat and lymph may prove essential to treating both. The vessels that drain our tissues, long overlooked, may hold one of the keys to the obesity epidemic.

Subject of Research: Bidirectional relationship between lymphatic dysfunction and obesity in metabolic disease pathogenesis and therapy

Article Title: Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment

Article References: Hao, Y., Zhang, Y., Zong, J., Wu, G., Wang, Y., Wang, J., & Wang, Y. (2026). Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02178-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02178-0

Keywords: obesity, lymphatic system, lymphatic dysfunction, VEGF-C, lacteals, lipid metabolism, inflammation, insulin resistance, lymphangiogenesis, adipokines, metabolic disease, lymphedema